

ASX ANNOUNCEMENT  
28 May 2020



## LGP CONTINUES RECORD-BREAKING SALES GROWTH

### Highlights:

- ✔ April 2020 - a record sales month with 1,850+ units sold, a 17% increase on March 2020 (previous record sales month)
- ✔ 380 new patients prescribed LGP products in April (for a cumulative total of over 3,550 patients) and 28 new prescribers
- ✔ The Office of Drug Control continues review of LGP's application for an expanded Cultivation Permit and has granted an extension to LGP's existing permit in the interim

**Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company")** is pleased to provide a sales update for the month of April 2020.

LGP achieved another record-breaking month in April 2020, with:

- sales of 1,850+ units of *LGP Classic* product (a new monthly record), a 17% increase on March 2020 sales;
- 380 new patients being prescribed LGP medicinal cannabis products (a cumulative total of 3,550+ patients have been prescribed LGP medicinal cannabis products as at 30 April 2020); and
- 28 new healthcare professionals prescribed LGP's products (for a total of 272 healthcare professionals prescribing LGP products).






**Commenting on the record monthly sales,  
Little Green Pharma Managing Director Fleta Solomon, said:**

*“Little Green Pharma’s continued growth trajectory in sales and patients is indicative of our determination to achieve our goal of delivering high quality and affordable medicinal cannabis products to our patients both domestically and globally. It is a testament to our hard work and further highlights the strong demand for our world-class suite of medicinal cannabis oil products.”*

**LGP sales and patients**



**Update on expanded Cultivation Permit applications**

The Office of Drug Control (“**ODC**”) continues to review LGP’s application for its expanded Cultivation Permits and in the interim has aligned LGP’s existing Cultivation Permits with the term of LGP’s expanded ODC Medicinal Cannabis Cultivation License (see ASX announcement dated 12 March 2020).

**ENDS**



## BY ORDER OF THE BOARD

A handwritten signature in black ink, appearing to read "Craig Basson", is written over a horizontal line.

### **Craig Basson**

Company Secretary

---

## For further information please contact:

Craig Basson, Company Secretary  
Little Green Pharma  
E: [craig@lgpharma.com.au](mailto:craig@lgpharma.com.au)  
M: +61 414 912 540

Celia Young, Marketing Manager  
Little Green Pharma  
E: [celia@lgpharma.com.au](mailto:celia@lgpharma.com.au)  
M: +61 421 730 885

## About Little Green Pharma

Little Green Pharma is a vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has an indoor cultivation facility in Western Australia and an exclusive partnership with a GMP-licensed pharmaceutical manufacturer for the production of its own-branded range of medicinal cannabis products.

Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medicinal-grade cannabis products to Australian and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: [www.littlegreenpharma.com](http://www.littlegreenpharma.com)

